Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for prevention and treatment of interstitial lung disease in COVID-19
ChiCTR2300067948Phase 4Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Feb 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of colchicine in coronavirus disease 2019 (COVID-19) and interstitial lung disease (ILD) (2 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoints: Incidence of interstitial lung disease and Warrick score. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)interstitial lung disease (ILD)
Beyond the preview
Go deeper on ChiCTR2300067948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067948.